SCM
PRTK

Suffolk Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Suffolk Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-52,007
Closed -$530K – 148
2018
Q2 		$530K Sell
52,007
-18,415
-26% -$208K 0.08% 109
2018
Q1 		$915K Hold
70,422
– – 0.13% 67
2017
Q4 		$1.26M Buy
70,422
+1,117
+2% +$23.3K 0.16% 57
2017
Q3 		$1.74M Buy
69,305
+15,439
+29% +$359K 0.23% 52
2017
Q2 		$1.3M Buy
53,866
+4,312
+9% +$95.3K 0.17% 107
2017
Q1 		$954K Buy
+49,554
New +$781K 0.13% 118

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Suffolk Capital Management's PRTK Position: Q3 2018 in Review

Suffolk Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2018, closing a stake of 52,007 shares — an estimated $530K sold.

Suffolk Capital Management first reported a position in PRTK in Q1 2017 and held it in 6 quarters. The position peaked at $1.74M in Q3 2017. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2018.

  • Suffolk Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Suffolk Capital Management sold 52,007 Paratek Pharmaceuticals, Inc. shares in Q3 2018, an estimated $530K.
  • Suffolk Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 6 quarters.
  • Suffolk Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $1.74M in Q3 2017.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2018.

Based on Suffolk Capital Management's 13F filing for Q3 2018, filed 9 Nov 2018.